Coherus BioSciences Inc
$ 1.45
-7.94%
05 Jun - close price
- Market Cap 223,662,000 USD
- Current Price $ 1.45
- High / Low $ 1.57 / 1.44
- Stock P/E N/A
- Book Value 0.51
- EPS -1.42
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.33 %
- ROE 0.33 %
- 52 Week High 2.62
- 52 Week Low 0.71
About
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. The company is headquartered in Redwood City, California.
Analyst Target Price
$7.80
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-11 | 2026-03-09 | 2025-11-06 | 2025-08-07 | 2025-05-12 | 2025-03-10 | 2024-11-06 | 2024-08-08 | 2024-05-09 | 2024-03-13 | 2023-11-06 | 2023-08-02 |
| Reported EPS | -0.25 | -0.34 | -0.38 | -0.34 | -0.35 | -0.28 | -0.09 | -0.14 | -0.32 | -0.62 | -0.27 | -0.38 |
| Estimated EPS | -0.26 | -0.3382 | -0.35 | -0.27 | -0.22 | -0.1305 | -0.26 | -0.26 | -0.21 | -0.12 | -0.24 | -0.44 |
| Surprise | 0.01 | -0.0018 | -0.03 | -0.07 | -0.13 | -0.1495 | 0.17 | 0.12 | -0.11 | -0.5 | -0.03 | 0.06 |
| Surprise Percentage | 3.8462% | -0.5322% | -8.5714% | -25.9259% | -59.0909% | -114.5594% | 65.3846% | 46.1538% | -52.381% | -416.6667% | -12.5% | 13.6364% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.08 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CHRS
2026-06-03 11:39:00
Coherus Oncology, Inc. announced the repricing of 3.2 million stock options for President & CEO Dennis M. Lanfear to an exercise price of $1.59 per share. These new options replace older ones with significantly higher exercise prices, a move approved by stockholders on May 29, 2026, and contingent on Lanfear remaining with the company through May 29, 2027. This adjustment aims to re-align his compensation with the current share price and provide new incentives.
2026-06-02 22:39:31
Coherus Biosciences (CHRS) announced the results of its 2026 Annual Meeting of Stockholders. Key outcomes include the election of Class III directors, ratification of Ernst & Young LLP as auditor, approval of executive compensation, and a reduction in the exercise price of certain stock options. Stockholders also authorized an increase in shares for its equity incentive plan to attract and retain talent.
2026-06-01 13:40:06
Coherus Oncology shareholders approved the election of two Class III directors, ratified the appointment of Ernst & Young LLP as their accounting firm, and approved executive compensation. Additionally, shareholders voted to reduce the exercise price of certain stock options and increase shares reserved under the 2014 Equity Incentive Award Plan. These decisions were made during their 2026 Annual Meeting of Stockholders, which included a partial adjournment for one proposal.
2026-05-21 02:10:12
Coherus BioSciences (CHRS) continues to experience high short interest and volatile trading as investors assess its oncology and biosimilar portfolios. The company, a US biotechnology firm, is strategically shifting towards high-margin oncology assets while managing its legacy biosimilar products. Investors are closely monitoring clinical trial data, regulatory milestones, and market dynamics to gauge the company's future financial performance and competitive position.
2026-05-15 16:40:08
Coherus Oncology reported its first-quarter 2026 financial results, highlighting LOQTORZI® net revenue of $11.8 million, a 61% increase year-over-year. The company also provided updates on its pipeline, including the completion of patient accrual for the 1L HCC Phase 2 clinical trial for casdozokitug and progress in the tagmokitug development program. Coherus ended the quarter with $167.0 million in cash, cash equivalents, and marketable securities.
2026-05-13 16:09:03
Coherus Oncology announced its first-quarter 2026 financial results, reporting $11.8 million in LOQTORZI net revenue, a 61% increase year-over-year. The company provided updates on its oncology pipeline, including the completion of patient accrual for the casdozokitug Phase 2 trial and advancements in the tagmokitug program. Coherus ended the quarter with $167.0 million in cash, cash equivalents, and marketable securities.
